Evidence map›Paper›PMID 24068615›Full record

ArticleMolecular neurobiology2014

Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase.

Yan Liu, Li Zeng, Keli Ma, Otto Baba, Pen Zheng, Yang Liu, Yin Wang

Abstract read
In one paragraph

Article in Molecular neurobiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. The regulation of glycogenolysis in the brain.The Journal of biological chemistry · 2018
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yan LiuCenter for Cancer and Immunology Research, Children's National Medical Center and George Washington University, 111 Michigan Avenue NW, Washington, DC, 20010, USA, ynliu@childrensnational.org.
Li Zeng
Keli Ma
Otto Baba
Pen Zheng
Yang Liu
Yin Wang
Children's National · USGeorge Washington University · USOhu University · JP

Funding

Molecular Pathological Mechanism & Potential Therapeutics of Lafora DiseaseR21NS062391 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIU, YAN NONE · 2009 to 2010
$409k
Molecular Programs for Stem Cells of Hematological MalignanciesR21CA164469 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, YIN · 2012 to 2013
$379k
NCI NIH HHS 5R21CA164469NCI NIH HHS R21 CA164469NINDS NIH HHS 1R21NS062391NINDS NIH HHS R21 NS062391
6 · The paper itself

Abstract

In Lafora disease (LD), the deficiency of either EPM2A or NHLRC1, the genes encoding the phosphatase laforin and E3 ligase, respectively, causes massive accumulation of less-branched glycogen inclusions, known as Lafora bodies, also called polyglucosan bodies (PBs), in several types of cells including neurons. The biochemical mechanism underlying the PB accumulation, however, remains undefined. We recently demonstrated that laforin is a phosphatase of muscle glycogen synthase (GS1) in PBs, and that laforin recruits malin, together reducing PBs. We show here that accomplishment of PB degradation requires a protein assembly consisting of at least four key enzymes: laforin and malin in a complex, and the glycogenolytic enzymes, glycogen debranching enzyme 1 (AGL1) and brain isoform glycogen phosphorylase (GPBB). Once GS1-synthesized polyglucosan accumulates into PBs, laforin recruits malin to the PBs where laforin dephosphorylates, and malin degrades the GS1 in concert with GPBB and AGL1, resulting in a breakdown of polyglucosan. Without fountional laforin-malin complex assembled on PBs, GPBB and AGL1 together are unable to efficiently breakdown polyglucosan. All these events take place on PBs and in cytoplasm. Deficiency of each of the four enzymes causes PB accumulation in the cytoplasm of affected cells. Demonstration of the molecular mechanisms underlying PB degradation lays a substantial biochemical foundation that may lead to understanding how PB metabolizes and why mutations of either EPM2A or NHLRC1 in humans cause LD. Mutations in AGL1 or GPBB may cause diseases related to PB accumulation.

Indexed as

AnimalsBrainCarrier ProteinsCell Line, TumorGlucansGlycogen Debranching Enzyme SystemGlycogen PhosphorylaseHEK293 CellsHumansIsoenzymesLafora DiseaseMiceMice, 129 StrainMice, Inbred C57BLMice, KnockoutProtein Tyrosine Phosphatases, Non-ReceptorCarrier ProteinsEPM2A protein, humanGlucansGlycogen Debranching Enzyme SystemGlycogen PhosphorylaseIsoenzymesNHLRC1 protein, humanpolyglucosanProtein Tyrosine Phosphatases, Non-ReceptorUbiquitin-Protein Ligases

Identifiers

PMID24068615
PMCPMC3954894
OpenAlexW2025533693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.